These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 34468946)

  • 1. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
    Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current advances in the treatment of systemic sclerosis.
    Bukiri H; Volkmann ER
    Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
    Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP
    Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].
    Lescoat A; Jouneau S; Uzunhan Y; Jégo P; Cottin V; Hachulla E
    Rev Med Interne; 2022 Jun; 43(6):365-374. PubMed ID: 35181160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
    Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
    Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.
    Chong WH; Saha BK; Beegle S
    Am J Med Sci; 2023 Feb; 365(2):198-204. PubMed ID: 35276077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
    Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
    Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?
    Duarte AC; Santos MJ; Cordeiro A
    Clin Rheumatol; 2018 Apr; 37(4):1123-1127. PubMed ID: 29038968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis.
    Aringer M; Riemekasten G
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101672. PubMed ID: 33745826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
    Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
    Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should we use nintedanib as early therapy in patients with SSc-ILD?
    Zanatta E; Moccaldi B; Szucs G; Spagnolo P
    Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
    Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.